Paul Herzich - Feb 13, 2024 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
Chief Technology Officer
Signature
/s/ David Tyronne Howton as attorney-in-fact for Paul Herzich
Stock symbol
SLDB
Transactions as of
Feb 13, 2024
Transactions value $
$0
Form type
4
Date filed
2/16/2024, 11:02 AM
Previous filing
Dec 5, 2023
Next filing
Dec 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SLDB Common Stock 6.02K Feb 13, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLDB Employee Stock Option (Right to Buy) Award $0 +57.5K $0.00 57.5K Feb 13, 2024 Common Stock 57.5K $7.85 Direct F2
transaction SLDB Restricted Stock Units Award $0 +28.8K $0.00 28.8K Feb 13, 2024 Common Stock 28.8K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,752 shares of the issuer's common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 30, 2023.
F2 This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.
F3 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").
F4 The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.